Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Featured news and events
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
Dementia design in built environment is 30 years behind physical disabilities movement ADI calls on governments to embed design in their national dementia responses under the Convention on the Rights for Persons with Disabilities Dementia design follows simple principles, is cost effective and dramatically improves enjoyment and safety of built environment…
A national dementia plan for China has been officially launched as a part of China’s Action Plan for Healthy China 2030.
Press release on COVID-19 deaths and dementia
At the beginning of World Alzheimer's Month, ADI highlights evidence that the COVID-19 pandemic is leading to extremely high death rates amongst people with dementia globally.
Two new reports highlight the challenges faced by health systems in the United States and five European countries to ensure preparedness for potentially imminent Alzheimer’s biomarker and treatment breakthroughs.
The Lancet launches new guidance which reveals that an extended set of 12 modifiable risk factors might prevent or delay up to 40 per cent of dementia cases globally.
The Dominican Republic’s Ministry of Public Health announces that the country will be launching a national dementia plan.